Sanofi and Cheplapharm announce strategic partnership for mature medicines portfolio

• Sanofi (NASDAQ:SNY) plans to transfer 20 mature medicines and three manufacturing sites to Cheplapharm under a strategic partnership.
• Sanofi will receive a 26.4% equity stake in Cheplapharm as part of the transaction.
• The partnership is designed to allow Sanofi to focus on innovation while Cheplapharm manages established medicines.

Sanofi (NASDAQ:SNY) and Cheplapharm announced plans to create a strategic partnership under which Cheplapharm would acquire a portfolio of 20 mature medicines and three manufacturing sites from Sanofi, with Sanofi receiving a 26.4% equity stake in Cheplapharm.

The transaction builds on a collaboration between the two companies that began in 2014 and follows Sanofi’s efforts to simplify its mature medicines portfolio while focusing resources on newer medicines and research programs.

“Our multi-year journey to simplify our mature portfolio has enabled us to focus on innovation while ensuring mature medicines continue to reach patients who need them,” said Thomas Grenier, Executive Vice President, General Medicines, Sanofi.

The transferred manufacturing sites include Csanyikvölgy in Hungary with about 400 employees, Jurong in Singapore with about 100 employees, and Ploërmel in France with about 65 employees, with existing employment arrangements and collective agreements expected to continue.

Sanofi develops medicines and vaccines across areas including immunology, oncology, rare diseases and general medicines, while Cheplapharm specializes in established pharmaceutical products and lifecycle management.

The commercial transfer of the medicine portfolio is planned to begin in the first quarter of 2027, followed by site transfers, subject to employee consultation procedures, regulatory approvals and other closing conditions, with completion expected in the third quarter of 2027.